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944Objective: To compare the potency, reversibility, and perioperative bleeding risk of Hepalean with those of PPC
heparin.
Methods: Because in vitro testing failed to detect differences in the potency or protamine reversibility of the 2
heparin preparations, we conducted a parallel group, single-center, double-blind, randomized, controlled trial to
compare the anticoagulant effects of Hepalean to those of PPC heparin in patients undergoing coronary artery
bypass grafting with cardiopulmonary bypass.
Results: From June 1, 2011, to June 30, 2011, we randomly assigned 11 patients to receive PPC heparin and 10
to receive Hepalean. Despite similar initial doses of heparin, the median initial activated clotting time was nu-
merically lower in the PPC heparin group than in the Hepalean group (median, 516.0 seconds; interquartile
range, 481.0-633.0; vs median, 584.0 seconds, interquartile range, 520.0-629.0; P ¼ .418). Those given PPC
heparin required a greater total heparin dose (median, 46,000.0 U; interquartile range, 39,500.0-60,000.0 vs me-
dian, 34,500.0 U; interquartile range, 32,250.0-37,000.0; P ¼ .011) and a greater dose of heparin per kilogram
than those given Hepalean (median, 572.9 U/kg; interquartile range, 443.0-659.7 vs median, 401.1 U/kg; inter-
quartile range, 400.0-419.4; P¼ .003). The key secondary results included an increased median total protamine
dose (median, 600.0 mg; interquartile range, 550.0-700.0; vs median, 500.0 mg; interquartile range, 425.0-
542.5; P¼ .026) and a trend toward increased chest tube output within 24 hours (median, 830.0 mL; interquartile
range, 425.0-1135.0; vs median, 702.5 mL; interquartile range, 550.0-742.5; P ¼ .324).
Conclusions: PPC heparin use was associated with greater heparin and protamine dose requirements than
Hepalean. These findings indicate that heparin preparations are not interchangeable and suggest that a direct
comparison of the potency with the brand in use is needed if a change is made to ensure that the agents exert
similar anticoagulant effects in vivo. (J Thorac Cardiovasc Surg 2012;144:944-50)Supplemental material is available online.eMcMaster UniversityMichael G. DeGroote School ofMedicine,a Hamilton,
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The Journal of Thoracic and Cardiovascular SurgMost cardiac surgical operations are performed using car-
diopulmonary bypass (CPB) that maintains the systemic
blood circulation during cardioplegia. Heparin is routinely
used to inhibit coagulation and prevent thrombus forma-
tion on the surfaces of the bypass circuitry and the
oxygenator.
In patients undergoing cardiac surgery, the first dose of
heparin is given before CPB, and the anticoagulant response
is monitored using a point-of-care device that measures the
activated clotting time (ACT).1,2 The usual target ACT
before CPB is at least 480 seconds.3,4 The ACT is
monitored throughout the procedure, and additional
heparin doses are given to maintain this ACT target. At
the end of the procedure, the anticoagulant effect of
heparin is reversed with protamine sulfate.5
Heparin is most commonly derived from porcine intesti-
nal mucosa, and several brands are commercially available.
Hamilton Health Sciences recently switched fromHepalean
(Organon Teknika, Toronto, Ontario, Canada) to Pharma-
ceutical Partners of Canada (PPC) heparin (PPC, Richmond
Hill, Ontario, Canada) because the production of Hepaleanery c October 2012
Abbreviations and Acronyms
ACT ¼ activated clotting time
aPTT ¼ activated partial thromboplastin time
CABG ¼ coronary artery bypass grafting
CPB ¼ cardiopulmonary bypass
PRP ¼ platelet-rich plasma
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Mwas discontinued. After switching heparin brands, cardiac
surgeons, anesthetists, perfusionists, and intensive care
unit staff had the impression that greater doses of PPC hep-
arin were needed to achieve a minimum threshold ACT,
more protamine was needed to reverse the effects of PPC
heparin, and the incidence of bleeding complications was
increased.
Differences in the potency between heparin brands have
been previously described in in vitro studies6 and have been
investigated clinically.7 In addition, investigators at several
institutions have reported differences in heparin and
protamine dosing when replacing Hepalean with PPC hep-
arin.8,9 However, differences between heparin brands have
not been rigorously evaluated in a randomized trial.
In response to the concerns of the cardiovascular surgical
team at our institution, we first conducted a retrospective au-
dit of patients treated with PPC heparin compared with his-
torical controls treated with Hepalean. Next, we performed
in vitro studies to compare the potency of the 2 heparin
brands. Because neither of these exploratory investigations
was conclusive, we then undertook a randomized controlled
trial to compare the anticoagulant effects and reversibility of
PPC heparin and Hepalean in patients undergoing coronary
artery bypass grafting (CABG) with CPB.
METHODS
All investigations were performed at the Hamilton General Hospital in
Hamilton, Ontario, Canada. Ethics approval was not required for the retro-
spective audit, because it was performed as a part of routine clinical care.
The Research Ethics Board of Hamilton Health Sciences approved the pro-
tocol for the randomized controlled trial. All participating patients pro-
vided written informed consent. The clinical trial registration number
was NCT01343381 (www.clinicaltrials.gov).
Phase I: Retrospective Chart Audit
We reviewed the medical records of 10 consecutive patients who had
undergone isolated CABG surgery by a single surgeon from January 12
to February 10, 2011, and received PPC heparin and compared them
with 10 consecutive patients undergoing isolated CABG from March 26
to April 27, 2010, who had received Hepalean. We collected the baseline
patient characteristics and operative data, including the amount of heparin
administered intraoperatively, ACTs, and protamine dosages. We recorded
the charted postoperative chest tube drainage, blood product requirements,
and the results of routine coagulation tests.
Phase II: In Vitro Studies
Venous blood samples were collected from5 healthy donors into 0.105-M
sodium citrate anticoagulated tubes and into 2 sets of 1-mL syringes prefilledThe Journal of Thoracic and Cawith 40 mL of differing concentrations of either PPC heparin or Hepalean.
The final concentration of each type of heparin in the syringes was 0.5, 1,
2, and 4 USPU/mL. As each syringewas filled, it was detached from the but-
terfly set, and the contents were dispensed into plastic test tubes to enable
thoroughmixing of the anticoagulant. ACT testingwas then performed using
a Hemochron Junior Signature Plus instrument (International Technidyne
Corporation, Edison, NJ) according to the manufacturer’s instructions. A sy-
ringe containing 40 mL of 0.15 M NaCl instead of heparin was collected last
and tested immediately to obtain a control ACTmeasurement for each donor.
Sodium citrate anticoagulated donor samples were centrifuged at 2000g for
10 minutes. Plasma was harvested and centrifuged again at 2000g for 10
minutes to minimize platelet contamination. The double-spun donor plasma
samples were frozen in aliquots at80C within 2 hours of collection and
thawed at 37C at assay.
Hepalean or PPC heparin was added to the donor plasma to yield the
final concentrations of 0.5, 1, 2, and 4 U/mL. An equal volume of 0.15
M NaCl was added to plasma instead of heparin as a baseline control.
The activated partial thromboplastin times (aPTTs) and anti-factor Xa
levels were determined. aPTT assays were performed using a Diagnostica
Stago coagulation analyzer (Diagnostica Stago, Parsippany, NJ) and Dade
Behring Actin FSL reagent (Dade-Behring, Marburg, Germany). Anti-
factor Xa assays were performed using an Amelung Sigma Amax 190 co-
agulation analyzer (Sigma Diagnostics, St Louis, Mo) and a Diagnostica
Stago Starchrom kit (Diagnostica Stago). The World Health Organization
international standard heparin (97/578) was used to construct the anti-
factor Xa standard curve. Plasma samples containing 1, 2, and 4 U/mL hep-
arin were diluted in pooled normal plasma to obtain anti-factor Xa levels
within the linear section of the standard curve. The pooled normal plasma
was tested to verify that the anti-factor Xa activity of the diluent was
negligible.
Whole blood samples containing PPC heparin or Hepalean at 4 U/mL
were obtained from the same 5 donors in syringes using the previously
described technique. The concentration of heparin was chosen to approx-
imate that usually achieved during CABG. The effect of the addition of 1,
3, or 5 mg of protamine sulfate on the ACT of the heparin anticoagulated
blood samples was determined. An equivalent volume of 0.15 M NaCl
was used instead of protamine sulfate as a control.
Platelet-rich plasma (PRP) was obtained from the 5 donors by centrifug-
ing 0.105 M sodium citrate anticoagulated blood samples at 200g for 8
minutes at room temperature. Platelet poor plasma was then obtained by
centrifuging the remainder of the sample at 2000g for 10 minutes. The
platelet count of the PRP was adjusted to 200 3 109/L by dilution with
platelet poor plasma. PPC heparin or Hepalean was added to the PRP at a fi-
nal concentration of 4 U/mL. An equal volume of 0.15 M NaCl was
substituted for heparin as a baseline control. Platelet aggregation studies
were performed on PRP using a Chrono-log 4 channel platelet aggregom-
eter (Chronolog, Havertown, Pa) according to the manufacturer’s instruc-
tions. Collagen (final concentration, 2 mg/mL) and adenosine
diphosphate (final concentration, 5 mM) were used as agonists, and 0.15
M NaCl was used as a negative control.
Phase III: Randomized Controlled Trial
Study design. We conducted a parallel-group, single-center, random-
ized, controlled trial. Patients undergoing CABG surgery with CPB were
stratified by urgent and elective status in blocks of 2 and 4 and randomly
assigned (1:1) by a computer-generated sequence to PPC heparin or
Hepalean.
Study participants. All adult patients (age,  18 years) undergoing
an isolated CABG procedure with CPB from June 1 to June 30, 2011, were
approached for recruitment into the present study by our research nurse. Pa-
tients with a history of allergy or intolerance to heparin and those who had
received unfractionated or low-molecular-weight heparin less than 24
hours before surgery were excluded. The size of the study was restricted
by the limited supply of Hepalean.rdiovascular Surgery c Volume 144, Number 4 945
TABLE 1. Results of retrospective audit of 20 patients undergoing
coronary artery bypass grafting
Variable
PPC heparin
(n ¼ 10)
Hepalean
(n ¼ 10)
P
value*
Initial heparin dose (U) .111
Median 40,000.0 36,500.0
Interquartile range 36,500.0-48,750.0 28,500.0-41,500.0
Initial heparin dose by
weight (U/kg)
.021
Median 440.7 407.4
Interquartile range 421.8-523.8 401.7-422.5
Total perioperative
heparin dose (U)
.495
Median 44,000.0 43,500.0
Interquartile range 40,250.0-53,750.0 35,750.0-48,750.0
Pre-CPB ACT (s) .570
Median 609.5 659.5
Interquartile range 545.8-659.5 555.5-928.3
Total protamine dose (mg) .038
Median 425.0 350.0
Interquartile range 400.0-500.0 323.8-400.0
Total protamine/100
U heparin (mg/100 U)
.082
Median 1.00 0.89
Interquartile range 0.27-0.85 0.78-0.94
ACT, Activated clotting time; CPB, cardiopulmonary bypass; PPC, Pharmaceutical
Partners of Canada. *For Wilcoxon-Mann-Whitney rank-sum test comparing Hepa-
lean and PPC groups.
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MStudy procedures. The participants were randomized preoperatively
to receive either PPC heparin or Hepalean during surgery. An unblinded re-
search pharmacist prepared the blinded study drug kits. The participants,
research nurse, surgeons, bedside nurses, outcome assessors, and statisti-
cians were all unaware of the treatment allocation; 10,000 U of study hep-
arin was used to prime the CPBmachine, and the initial heparin dose given
to each patient was 400 U/kg. If an appropriate ACT for CPB (defined for
the present study as 480 seconds) was not achieved, additional heparin
boluses were administered in increments of 5000 U until the target ACT
was achieved. Once achieved, CPB was initiated, and surgery proceeded
according to the usual practice. If needed, additional heparin (in increments
of 5000 U) was given during the surgery according to usual practice. At the
end of surgery, protaminewas administered at an initial dosage of 1 mg/100
U of heparin given during the surgery. Additional doses of protamine were
given as needed according to usual care. The postoperative patient care fol-
lowed standard best practice guidelines. The patients were followed up
postoperatively for 24 hours. The chest tube output, protamine and blood
product administration, and occurrence of reoperation for bleeding or car-
diac tamponade were recorded during this period.
Blood samples were collected into sodium citrate tubes at 4 points dur-
ing the study: preoperatively, after administration of the initial dose of hep-
arin, after 45 minutes of CPB, and after the initial protamine
administration. The plasma was separated using a double-centrifugation
technique, spinning the sample twice at 2000g for 10 minutes. The sepa-
rated plasma was distributed into 5 aliquots at each point and frozen in
a 80C freezer within 2 hours of collection. The anti-factor Xa levels
and aPTTs were obtained for each of the blood samples using the methods
described.
Study outcomes. The primary outcomes were the ACTmeasured im-
mediately after the initial weight-adjusted dose of heparin and the total
weight-adjusted heparin dose administered during CPB.
The secondary outcomes were the ACTmeasured immediately after the
initial weight-adjusted protamine dose at the end of the procedure; total
protamine dose administered to neutralize heparin anticoagulation; blood
loss, which was evaluated by the total chest tube output, number of units
transfused, and the need for reoperation for bleeding or cardiac tamponade;
and the results of the coagulation blood tests, including anti-factor Xa level
and aPTT measured after administration of the initial dose of heparin, after
45 minutes of CPB, and after initial protamine administration.
Statistical analysis. All analyses were conducted in a blinded fash-
ion. Continuous data are presented as the median and interquartile range or
mean  standard deviation, and categorical data are presented as numbers
and proportions. The baseline, intraoperative, and postoperative data were
compared using the Wilcoxon-Mann-Whitney rank sum test for nonpara-
metric variables, except for age, weight, height, and body surface area,
which were compared using Student t tests. Categorical variables were
compared using Fisher’s exact test. All P values were 2 sided.RESULTS
Phase I: Audit
The results of our retrospective audit are listed in Table 1.
Compared with the 10 historical controls who received
Hepalean, the 10 PPC heparin recipients required a signifi-
cantly greater initial dose of heparin by weight to achieve an
ACT of 480 seconds (median, 440.7 U/kg; interquartile
range, 421.8-523.8; vs median, 407.4 U/kg; interquartile
range, 401.7-422.5; P ¼ .021). The total protamine dose
given in the operating room and intensive care unit was
significantly greater in the PPC heparin group than in the
Hepalean group (median, 425.0 mg; interquartile range,
400.0-500.0; vs median, 350.0 mg; interquartile range,946 The Journal of Thoracic and Cardiovascular Surg323.8-400.0; P ¼ .038). The protamine dose remained nu-
merically greater after adjusting for the total amount of hep-
arin administered, although the difference was no longer
statistically significant (median, 1.00 mg/100 U heparin; in-
terquartile range, 0.27-0.85; vs median, 0.89 mg/100 U hep-
arin, interquartile range, 0.78-0.94; P ¼ .082). No
significant difference was found between the 2 groups in
the bleeding outcomes.Phase II: In Vitro Studies
According to the ACT, aPTT, and anti-factor Xa levels,
PPC heparin and Hepalean had similar anticoagulant activ-
ity (Figures E1 and E2). Both brands of heparin were re-
versed with protamine in a similar manner (Figure E3).
Platelet aggregation in response to collagen or ADP was
similarly affected by PPC heparin and Hepalean (Figure 1).Phase III: Randomized Controlled Trial
The patient flow is shown in Figure E4. A total of 60 pa-
tients were screened, and 23 patients agreed to participate.
Of the 23 patients, 2 were not randomized; the first patient
underwent emergency surgery during off hours and the sec-
ond patient received 10,000 U of nonstudy heparin at CPB
prime. The remaining 21 patients were randomized to PPC
heparin (n ¼ 11) or Hepalean (n ¼ 10).ery c October 2012
FIGURE 1. Molecular weight distribution of Hepalean and PPC Heparin.
PPC, Pharmaceutical Partners of Canada.
TABLE 2. Baseline patient characteristics and details of surgery
according to randomized treatment allocation
Characteristic
PPC heparin
(n ¼ 11)
Hepalean
(n ¼ 10)
P
value
Gender (n) —
Male 11 9
Female 0 1
Age (y) 63.9  10.9 68.7  14.2 .394*
Weight (kg) 89.3  16.9 82.0  16.0 .327*
Height (cm) 172.5  7.1 170.0  7.9 .446*
Body surface area (m2) 2.06  0.22 1.95  0.22 .277*
Creatinine (mmol/L) .217y
Median 91.0 78.0
Interquartile range 79.0-110.0 73.5-91.0
Hemoglobin (g/L) .944y
Median 142.0 146.0
Interquartile range 128.5-148.5 132.3-149.3
Platelet count (3109/L) .024y
Median 222.0 181.5
Interquartile range 205.5-255.0 162.0-207.8
International normalized ratio .079y
Median 1.0 1.1
Interquartile range 1.0-1.0 1.0-1.1
PTT (s) .287y
Median 33.0 31.5
Interquartile range 32.0-35.0 31.0-33.8
TCT 2 unit (s) .337y
Median 23.0 24.0
Interquartile range 22.0-24.0 23.8-24.3
Surgery type (n) —
Urgent 6 5
Elective 5 5
Grafts (n) .454y
Median 4.0 4.0
Interquartile range 3.0-4.5 3.0-4.0
CPB duration (h) .503y
Median 1.32 1.52
Interquartile range 1.14-1.64 1.33-1.71
Data presented as mean standard deviation, median and interquartile range, or num-
bers of patients. CPB, Cardiopulmonary bypass; PPC, Pharmaceutical Partners of
Canada; TCT, thrombin clotting time; PTT, partial thromboplastin time. *Two-sided
Student’s t-test. yWilcoxon-Mann-Whitney rank sum test.
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MThe baseline and surgical characteristics are displayed in
Table 2. The 2 groups were similar in all baseline character-
istics, except for the preoperative platelet count, which was
slightly greater in the PPC heparin group. All patients un-
derwent isolated CABG surgery with CPB and received 2
to 7 grafts. All procedures used the left internal mammary
artery. Two procedures, 1 in each group, also used the right
internal mammary artery.
Primary outcomes. The data regarding heparin and prot-
amine dosing are listed in Table 3. Despite similar median
initial doses of PPC heparin and Hepalean (median, 404.5
and 400.5 U/kg, respectively), according to the study proto-
col, the patients in the PPC heparin group had a numerically
lower initial ACT than the Hepalean group (median, 516.0
seconds; interquartile range, 481.0-633.0; vs median, 584.0
seconds; interquartile range, 520.0-629.0; P ¼ .418).
The median total amount of heparin administered during
CPB was significantly greater in the PPC heparin group
than in the Hepalean group (median, 46,000.0 U; interquar-
tile range, 39,500.0-60000.0; vs median, 34,500.0 U; inter-
quartile range, 32,250.0-37,000.0; P ¼ .011). This
difference remained evident after adjustment for body
weight (median, 572.9 U/kg; interquartile range, 443.0-
659.7; vs 401.1 U/kg; interquartile range, 400.0-419.4;
P ¼ .003). Two patients, both in the PPC heparin group,
failed to achieve the minimum target ACT of 480 seconds
after the first dose of heparin and required additional doses.
Also, 8 patients in the PPC heparin group and 2 in the Hep-
alean group (P¼ .030) required additional doses of heparin
during surgery; an average of 211.3 U/kg in the PPC heparin
group and 21.2 U/kg in the Hepalean group. The heparin
dose by weight and the ACT values after the first dose of
heparin and after subsequent heparin doses are shown in
Figure E5.
Secondary outcomes. The results of coagulation testing
are listed in Table 4.
The initial protamine dosage was determined from the to-
tal heparin dosage administered during surgery. No signifi-
cant difference was found between the 2 groups in the ACTs
achieved after the initial protamine dose (median, 112.0The Journal of Thoracic and Caseconds; interquartile range, 107.5-117.3; vs median,
113.5 seconds; interquartile range, 112.0-114.0;
P ¼ .721). However, the patients receiving PPC heparin
had significantly greater aPTT values than those receiving
Hepalean (median, 38.20 seconds; interquartile range,
36.25-50.90; vs median, 35.30 seconds; interquartile range,
34.0-41.03; P ¼ .049). In addition, 9 patients in the PPC
heparin group compared with 4 patients in the Hepalean
group received additional protamine in the intensive care
unit (P ¼ .081). The decision to administer additional prot-
amine to these patients was determined by clinical consid-
erations (eg, continued oozing, excessive chest tube
drainage) rather than the laboratory test results. The median
total protamine dose was significantly greater in therdiovascular Surgery c Volume 144, Number 4 947
TABLE 3. Heparin and protamine dosing according to randomized
treatment allocation
Dosing
PPC heparin
(n ¼ 11)
Hepalean
(n ¼ 10)
P
value*
Heparin
Initial dose/weight
(U/kg)
.285
Median 404.5 400.5
Interquartile range 401.4-413.3 400.0-402.8
ACT after initial
dosey (s)
.418
Median 516.0 584.0
Interquartile range 481.0-633.0 520.0-629.0
Total administered (U) .011
Median 46,000.0 34,500.0
Interquartile range 39,500.0-60,000.0 32,250.0-37,000.0
Total dose by
weight (U/kg)
.003
Median 572.9 401.1
Interquartile range 443.0-659.7 400.0-419.4
Protamine
Initial dose (mg) .222
Median 500.0 435.0
Interquartile range 425.0-525.0 362.5-492.5
ACT after initial dose (s) .721
Median 112.0 113.5
Interquartile range 107.5-117.3 112.0-114.0
Total intraoperative
dose (mg)
.110
Median 550.0 475.0
Interquartile range 500.0-675.0 412.5-515.0
Administered in
ICU (mg)
.048
Median 50.0 0.0
Interquartile range 50.0-50.0 0.0-50.0
Total administered (mg) .026
Median 600.0 500.0
Interquartile range 550.0-700.0 425.0-542.5
Total dose/100 U
heparin (mg/100 U)
.132
Median 1.3 1.4
Interquartile range 1.1-1.4 1.3-1.5
ACT,Activated clotting time; ICU, intensive care unit; PPC, Pharmaceutical Partners
of Canada. *Wilcoxon-Mann-Whitney rank sum test. yTwo patients (one in each
group) had an initial ACT>1000-s limit of measurement; these values were consid-
ered to be 1000 for this analysis.
TABLE 4. Results of coagulation testing according to randomized
treatment allocation
Sample
PPC heparin
(n ¼ 11)
Hepalean
(n ¼ 10)
P
value*
UFH anti-factor Xa (U/mL)
Baseline .639
Median 0.05 0.05
Interquartile range 0.05-0.19 0.05-0.10
After initial heparin .698
Median 8.10 7.65
Interquartile range 7.05-8.78 6.68-8.25
After 45 min on CPB .098
Median 7.50 6.47
Interquartile range 6.53-8.70 5.66-6.86
After initial protamine .246
Median 0.09 0.06
Interquartile range 0.06-0.18 0.05-0.11
PTT (s)y
Baseline .472
Median 37.60 36.95
Interquartile range 35.60-40.70 34.95-38.85
After initial heparin —
Median 300.00 300.00
Interquartile range 300.00-300.00 300.00-300.00
After 45 min on CPB —
Median 300.00 300.00
Interquartile range 300.00-300.00 300.00-300.00
After initial protamine .049
Median 38.20 35.30
Interquartile range 36.25-50.90 34.0-41.03
AT (U/mL)
Baseline .910
Median 0.97 0.90
Interquartile range 0.79-1.04 0.84-1.03
After initial heparin .698
Median 1.08 1.00
Interquartile range 0.94-1.15 0.93-1.15
AT, Antithrombin; CPB, cardiopulmonary bypass; PPC, Pharmaceutical Partners of
Canada; PTT, partial thromboplastin time; UFH, unfractionated heparin. *Wil-
coxon-Mann-Whitney rank sum test. yMaximum measureable PTT, 300 s.
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Mpatients receiving PPC heparin than in those receiving Hep-
alean (median, 600.0 mg; interquartile range, 550.0-700.0;
vs median, 500.0 mg; interquartile range, 425.0-542.5;
P ¼ .026).
Bleeding outcomes and the amount of blood products
administered are listed in Table E1. A trend was seen toward
increased postoperative bleeding in the group receiving
PPC heparin compared with the Hepalean group, as
determined by the total chest tube output (median, 830.0;
interquartile range, 425.0-1135.0; vs median, 702.5; inter-
quartile range, 550.0-742.5; P ¼ .3240). The bleeding948 The Journal of Thoracic and Cardiovascular Surgindexes were similar in the 2 groups, and no patients re-
turned to the operating room for re-exploration for bleeding.
DISCUSSION
The results of our retrospective chart review suggested an
increase in heparin requirements for PPC heparin compared
with Hepalean, but our in vitro studies provided no evidence
of differences in the potency of the 2 heparins. Therefore,
we performed a randomized trial, which, although restricted
in size by the lack of availability of Hepalean, showed that
in patients undergoing CABG surgery with CPB, those pa-
tients receiving PPC heparin had numerically lower ACT
levels after initial heparin administration, required signifi-
cantly greater doses of heparin during surgery, and dis-
played a trend toward increased postoperative bleeding.
These results have confirmed the anecdotal observationsery c October 2012
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Mmade by the cardiovascular surgery team and the results of
our retrospective audit.
The small sample size of our study was dictated by the
lack of Hepalean. Despite this limitation, a significant and
substantial difference was found in the total dose of heparin
required to reach and maintain the target ACT in the PPC
heparin group compared with the Hepalean group. Also,
correspondingly, the total dose of protamine required to re-
verse the anticoagulant effect was also greater in the PPC
heparin group.
Our results are consistent with previous reports of differ-
ences in the anticoagulant response when switching from 1
heparin to another in patients undergoing bypass surgery. In
2005, the London Health Sciences Centre in London, On-
tario, Canada noted in a retrospective study that when
they replaced Hepalean with PPC heparin, the number of
blood transfusions were greater in the patients who received
PPC heparin (51.3% vs 47.7%; P ¼ .09) and that reopera-
tion for bleeding occurred more frequently (4.3% vs 2.7%;
P ¼ .057). After switching back to Hepalean, a reversal of
these trends occurred.8 Prompted by the concerns raised by
other centers about the potential for increased bleeding with
PPC heparin, the investigators at the Hospital for Sick Chil-
dren (Toronto, Ontario, Canada) undertook a retrospective
cohort study involving 903 pediatric cardiac surgery pa-
tients.8,9 Compared with Hepalean, these investigators
found that PPC heparin was associated with increased red
blood cell transfusions in the first 24 hours and an
increased risk of hemorrhagic complications (odds ratio,
7.0; 95% confidence interval, 2.0-24.2) and early
reoperation (odds ratio, 5.3; 95% confidence interval,
1.0-28.0).
Our randomized study mandated that both groups re-
ceived the same initial dose of heparin, and our primary out-
comes were the ACTmeasured immediately after the initial
weight-adjusted dose of heparin and the total weight-
adjusted heparin dose administered during CPB. A nonsig-
nificant trend was seen for the initial postheparin ACT to be
lower in the PPC heparin group than in the Hepalean group.
Furthermore, the ACT of many patients decreased during
surgery, leading to the administration of additional doses
of heparin to maintain the ACT within the target range. In
the PPC heparin group, an additional 211.3 U/kg was re-
quired during the procedure, but in the Hepalean group,
only an additional 21.2 U/kg was required. The reason for
this marked difference in heparin dosage requirements to
maintain the ACT in the target range remains to be deter-
mined but might be explained by differences in clearance
or protein binding of the 2 heparin preparations. The subse-
quent trend toward increased bleeding and a significant in-
crease in protamine requirement is consistent with the
findings of the observational studies reviewed and the re-
sults of our retrospective chart review and can be explained
by the heparin rebound resulting from the greater heparinThe Journal of Thoracic and Cadose given to the PPC heparin group. Heparin rebound is
well recognized after CPB and occurs as a result of the
re-entry of heparin from the extravascular to the intravascu-
lar space and the release of protein-bound heparin after rou-
tine heparin neutralization by protamine. Because the
heparin–protamine complex is rapidly cleared in the urine,
the heparin that re-enters the circulation has the potential to
cause postoperative bleeding.10,11 In our study, despite the
initial postprocedure protamine dose used for
neutralization, the aPTT and subsequent protamine doses
were significantly greater in the PPC heparin group than
in the Hepalean group. Both these observations can be
plausibly explained by greater heparin rebound in the
PPC heparin group. Studies are currently underway to
explore the mechanism of the pharmacologic differences
of the 2 heparins.
Within the medical community, it has long been assumed
that all unfractionated heparin preparations are the same.
PPC heparin and Hepalean are both marketed under the
U.S. Pharmacopeia unfractionated heparin monograph
standards. Under this regulation, they are required to have
similar efficacy, potency, and reversibility. However, the
findings of previous work, combined with our results, sug-
gest that important clinical difference exist between PPC
heparin and Hepalean that cannot be predicted with the
usual in vitro tests.
Our results indicate that heparin preparations might not
interchangeable despite identical anticoagulant profiles
in vitro. We therefore suggest that if a change in heparins
is made for CPB surgery, the anticoagulant profile of the
new heparin should be compared with the brand in use by
performing a chart review similar to the one we performed.
If differences are found, our studies could provide a tem-
plate for their additional investigation.
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FIGURE E1. Activated clotting times (ACTs) for various concentrations
of Hepalean and PPC heparin. PPC, Pharmaceutical Partners of Canada.
FIGURE E2. Anti-factor Xa activity for various concentrations of Hepa-
lean and PPC heparin. PPC, Pharmaceutical Partners of Canada.
FIGURE E3. In vitro study of protamine reversal of Hepalean and PPC
heparin. PPC, Pharmaceutical Partners of Canada; ACT, activated clotting
time.
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FIGURE E4. Consort flow diagram. PPC, Pharmaceutical Partners of Canada.
FIGURE E5. Heparin dose by weight at each dose and resulting activated
clotting time (ACT). PPC, Pharmaceutical Partners of Canada; CPB, car-
diopulmonary bypass.
Perioperative Management Arsenault et al
950.e2 The Journal of Thoracic and Cardiovascular Surgery c October 2012
P
M
TABLE E1. Blood product use and bleeding outcomes according to
randomized treatment allocation
Blood product use and
bleeding outcomes
PPC heparin
(n ¼ 11)
Hepalean
(n ¼ 10)
P
value*
Intraoperative blood products
Intraoperative PRBCs (U) .801
Median 0.0 0.0
Interquartile range 0.0-1.5 0.0-1.5
Intraoperative FFP (mL) .189
Median 0.0 0.0
Interquartile range 0.0-0.0 0.0-0.0
Intraoperative platelets (mL) .189
Median 0.0 0.0
Interquartile range 0.0-0.0 0.0-0.0
Intraoperative
cryoprecipitate (mL)
—
Median 0.0 0.0
Interquartile range 0.0-0.0 0.0-0.0
Postoperative blood products
Postoperative PRBCs (U) .304
Median 0.0 0.0
Interquartile range 0.0-0.5 0.0-0.0
Postoperative FFP (mL) .146
Median 0.0 0.0
Interquartile range 0.0-0.0 0.0-0.0
Postoperative
platelets (mL)
.968
Median 0.0 0.0
Interquartile range 0.0-335.0 0.0-340.0
Postoperative
cryoprecipitate (mL)
—
Median 0.0 0.0
Interquartile range 0.0-0.0 0.0-0.0
Bleeding outcomes
Total chest tube
output (mL)
.324
Median 830.0 702.5
Interquartile range 425.0-1135.0 550.0-742.5
24-h Postoperative
hemoglobin (g/L)
.397
Median 96.0 87.5
Interquartile range 86.0-100.5 82.3-96.3
Total change in
hemoglobin (g/L)
.672
Median 43.0 46.0
Interquartile range 37.0 to47.5 24.5 to60.5
FFP, Fresh frozen plasma; PRBCs, packed red blood cells; PPC, Pharmaceutical
Partners of Canada. *Wilcoxon-Mann-Whitney rank sum test.
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